ClinicalTrials.gg

Program

epetraborole

Also written as “Epetraborole”, “GSK2251052” and “AN3365”.

Its studies are mostly in Community-Acquired Infections · Polycythemia Vera · Respiratory Tract Infections · Renal Insufficiency · Gram-Negative Bacterial Infections, led by 3 companies.

Furthest: phase 3, since Jun 9, 201113 company-led studies, 1 open or runningNext primary completion: Apr 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline70 open or runningphase 2since Jun 9, 2011Dec 16, 2010none ahead
AN2 Therapeutics51 open or runningphase 3since Mar 24, 2022May 11, 2021Apr 2029phase 2 · NCT07891533
Pfizer10 open or runningphase 1since Oct 20, 2009Oct 20, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 20, 2009First study: phase 1 study in Gram-Negative Bacterial InfectionsNew to PfizerPfizer · NCT01015014 · 64 enrolled · Australia
  2. Dec 16, 2010GlaxoSmithKline's first studies: 2 phase 1 studiesNew to GlaxoSmithKlineGlaxoSmithKline · NCT01267968, NCT01262885
  3. Jun 9, 20112 phase 2 studiesGlaxoSmithKline · NCT01381562, NCT01381549
  4. Nov 17, 2011Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01475695 · 6 enrolled · Netherlands
  5. Dec 15, 2011Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01495065 · 8 enrolled · United States
  6. Sep 20, 2012Phase 1 study in Community-Acquired InfectionsGlaxoSmithKline · NCT01702350 · 24 enrolled · Australia
  7. May 11, 2021AN2 Therapeutics's first study: phase 1 study in Healthy VolunteersNew to AN2 TherapeuticsAN2 Therapeutics · NCT04892641 · 51 enrolled · Australia
  8. Feb 17, 2022Phase 1 study in Renal InsufficiencyAN2 Therapeutics · NCT05283746 · 40 enrolled · United States
  9. Mar 24, 2022Phase 3 study in Respiratory Tract InfectionsAN2 Therapeutics · NCT05327803 · 177 enrolled · United States, Australia, Japan and more
  10. Jun 27, 2023Phase 1 study in Healthy VolunteersAN2 Therapeutics · NCT05995444 · 24 enrolled · United States
  11. Oct 17, 2026Phase 2 study in Polycythemia VeraAN2 Therapeutics · NCT07891533 · 75 planned · Australia

Ahead

  1. Apr 2029Primary completion: phase 2 study in Polycythemia VeraAN2 Therapeutics · NCT07891533

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Leucine--tRNA ligase inhibitor”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07891533Polycythemia Vera · Australia2Not yet recruitingAN2 TherapeuticsApr 202975
NCT05995444Healthy Volunteers · United States1CompletedAN2 TherapeuticsJul 26, 202324
NCT05327803Respiratory Tract Infections · United States, Australia, Japan and more3TerminatedAN2 TherapeuticsDec 18, 2024177
NCT05283746Renal Insufficiency · United States1CompletedAN2 TherapeuticsJun 10, 202240
NCT04892641Healthy Volunteers · Australia1CompletedAN2 TherapeuticsFeb 26, 202251
NCT01702350Community-Acquired Infections · Australia1TerminatedGlaxoSmithKlineDec 8, 201124
NCT01495065Community-Acquired Infections · United States1TerminatedGlaxoSmithKlineFeb 17, 20128
NCT01475695Community-Acquired Infections · Netherlands1CompletedGlaxoSmithKlineMay 19, 20116
NCT01381562Infections · United States, Canada, Czechia and more2TerminatedGlaxoSmithKlineMar 5, 201215
NCT01381549Urinary Tract Infections · United States, Canada, France and more2TerminatedGlaxoSmithKlineMar 6, 201220
NCT01267968Community-Acquired Infections · United States1CompletedGlaxoSmithKlineMar 16, 201125
NCT01262885Bacterial Infections · Australia1CompletedGlaxoSmithKlineAug 25, 201184
NCT01015014Gram-Negative Bacterial Infections · Australia1CompletedPfizerMay 13, 201064

How it is read

Names in the registry

  • “Epetraborole”, 5 entries
  • “GSK2251052”, 4 entries
  • “AN3365”, 1 entry
  • “Drug: GSK2251052”, 1 entry
  • “14C GSK2251052”, 1 entry

Codes read as this program: GSK2251052.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.